Abstract
Hepatitis C virus (HCV) infection is a common cause of chronic liver disease and a serious threat to human health. The HCV NS3/4A serine protease is necessary for viral replication and innate immune evasion, and represents a well-validated target for specific antiviral therapy. We previously reported the isolation of single-chain antibodies (scFvs) that inhibit NS3/4A protease activity in vitro. Expressed intracellularly (intrabodies), these scFvs blocked NS3-mediated proliferation of NS3-transfected cells. Here we show that anti-NS3 scFvs suppress HCV RNA replication when expressed intracellularly in Huh7 hepatoma cells bearing either subgenomic or genome-length HCV RNA replicons. The expression of intrabodies directed against NS3 inhibited the autonomous amplification of HCV replicons resistant to small-molecule inhibitors of the NS3/4A protease, and replicons derived from different HCV genotypes. The combination of intrabodies and interferon-α had an additive inhibitory effect on RNA replication in the replicon model. Intrabody expression also inhibited production of infectious HCV in a cell culture system. The NS3 protease activity was inhibited by the intrabodies in NS3-expressing cells. In contrast, cell-free synthesis of HCV RNA by preformed replicase complexes was not inhibited by intrabodies, suggesting that the major mode of inhibition of viral replication is inhibition of NS3/4A protease activity and subsequent suppression of viral polyprotein processing.
| Original language | English |
|---|---|
| Pages (from-to) | 95-106 |
| Number of pages | 12 |
| Journal | Antiviral Research |
| Volume | 88 |
| Issue number | 1 |
| DOIs | |
| State | Published - Oct 2010 |
| Externally published | Yes |
Bibliographical note
Funding Information:We thank Dr. Matti Sällberg (Karolinska Institute, Sweden) for providing the plasmid-carrying the NS3-4A gene of the 1a genotype. This work was supported in part by the Caesarea Edmond Benjamin De Rothschild Foundation, Israel (RTK, RZ), by a grant from the United States-Israel Binational Science Foundation (BSF), Israel (RTK, IB, SML), and by the National Institute of Allergy and Infectious Diseases , U.S, through the following grants and contracts: U19-AI40035 and N01-AI25488 (SML). M.G.-T. was the recipient of a McLaughlin Post-doctoral Research Fellowship, while R.J. is a McLaughlin Pre-doctoral Fellow.
Funding
We thank Dr. Matti Sällberg (Karolinska Institute, Sweden) for providing the plasmid-carrying the NS3-4A gene of the 1a genotype. This work was supported in part by the Caesarea Edmond Benjamin De Rothschild Foundation, Israel (RTK, RZ), by a grant from the United States-Israel Binational Science Foundation (BSF), Israel (RTK, IB, SML), and by the National Institute of Allergy and Infectious Diseases , U.S, through the following grants and contracts: U19-AI40035 and N01-AI25488 (SML). M.G.-T. was the recipient of a McLaughlin Post-doctoral Research Fellowship, while R.J. is a McLaughlin Pre-doctoral Fellow.
| Funders | Funder number |
|---|---|
| National Institute of Allergy and Infectious Diseases | U19AI040035, N01-AI25488 |
| United States-Israel Binational Science Foundation |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Hepatitis C virus
- Inhibitors
- Intrabodies
- NS3 protease
- RNA replicons
- Single-chain antibodies
Fingerprint
Dive into the research topics of 'Inhibition of protease-inhibitor-resistant hepatitis C virus replicons and infectious virus by intracellular intrabodies'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver